Annexin A2 promotes glioma cell invasion and tumor progression

Journal of Neuroscience

Volumn 31, Issue 40, 2011, Pages 14346-14360

  Zhai, Haiyan ^a   Acharya, Suchitra ^b   Gravanis, Iordanis ^a   Mehmood, Saira ^a   Seidman, Roberta J ^a   Shroyer, Kenneth R ^a   Hajjar, Katherine A ^b   Tsirka, Stella E ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; ENHANCED GREEN FLUORESCENT PROTEIN; LIPOCORTIN 2; PLASMIN; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR; TUBULIN;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CELL CLONE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; GLIOMA CELL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMBRANE BINDING; MOUSE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCHOOL CHILD; TUMOR VOLUME;

ANIMALS; ANNEXIN A2; BRAIN NEOPLASMS; CELL LINE; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE KNOCKDOWN TECHNIQUES; GLIOMA; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; PILOT PROJECTS; RATS; RATS, INBRED F344;

EID: 80053655299     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3299-11.2011     Document Type: Article

References (90)

1. Allegranza A, Girlando S, Arrigoni GL, Veronese S, Mauri FA, Gambacorta M, Pollo B, Dalla Palma P, Barbareschi M (1991) Proliferating cell nuclear antigen expression in central nervous system neoplasms. Virchows Arch A Pathol Anat Histopathol 419:417-423.
2. Amberger VR, Hensel T, Ogata N, Schwab ME (1998) Spreading and migra-tionofhuman glioma and rat C6cellson central nervous system myelinin vitro is correlated with tumor malignancy and involves a metalloproteo-lytic activity. Cancer Res 58:149-158.
3. Bao H, Jiang M, Zhu M, Sheng F, Ruan J, Ruan C (2009) Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol 90:177-185.
4. Barth RF, Kaur B (2009) Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol 94:299-312.
5. Beckner ME, Chen X, An J, Day BW, Pollack IF (2005) Proteomic characterization of harvested pseudopodia with differential gel electrophoresis and specific antibodies. Lab Invest 85:316-327.
6. Benda P, Lightbody J, Sato G, Levine L, Sweet W (1968) Differentiated rat glial cell strain in tissue culture. Science 161:370-371.
7. Boschek CB, Jockusch BM, Friis RR, Back R, Grundmann E, Bauer H (1981) Early changes in the distribution and organization of microfilament proteins during cell transformation. Cell 24:175-184.
8. Campa C, Kasman I, Ye W, Lee WP, Fuh G, Ferrara N (2008) Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovas-cularization in mice: optimizing methods to quantify vascular changes. Invest Ophthalmol Vis Sci 49:1178-1183.
9. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaître V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D (1997) Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17:439-444.
10. Chiang Y, Schneiderman MH, Vishwanatha JK (1993) Annexin II expression is regulated during mammalian cell cycle. Cancer Res 53:6017-6021.
11. Chung CY, Erickson HP (1994) Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J Cell Biol 126:539-548.
12. Chung CY, Murphy-Ullrich JE, Erickson HP (1996) Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell 7:883-892.
13. Collen D (1999) The plasminogen (fibrinolytic) system. Thromb Haemost 82:259-270.
14. Colman H, Giannini C, Huang L, Gonzalez J, Hess K, Bruner J, Fuller G, Langford L, Pelloski C, Aaron J, Burger P, Aldape K (2006) Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocy-tomas. Am J Surg Pathol 30:657-664.
15. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15:1913-1925.
16. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139-266.
17. Dassah M, Deora AB, He K, Hajjar KA (2009) The endothelial cell annexin A2 system and vascular fibrinolysis. Gen Physiol Biophys 28:F20-F28.
18. DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114-123.
19. DeClerck YA, Imren S, Montgomery AM, Mueller BM, Reisfeld RA, Laug WE (1997) Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol 425:89-97.
20. Deryugina EI, Bourdon MA (1996) Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin. J Cell Sci 109:643-652.
21. Díaz VM, Hurtado M, Thomson TM, Reventós J, Paciucci R (2004) Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut 53:993-1000.
22. Eberhard DA, Brown MD, VandenBerg SR (1994) Alterations of annexin expression in pathological neuronal and glial reactions. Immunohisto-chemical localization of annexins I, II (p36 and p11 subunits), IV, and VI in the human hippocampus. Am J Pathol 145:640-649.
23. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS (2006) Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 54:526-535.
24. Eyüpoglu IY, Hahnen E, Heckel A, Siebzehnrübl FA, Buslei R, Fahlbusch R, Blümcke I (2005) Malignant glioma-induced neuronal cell death in an organotypic glioma invasion model. Technical note. J Neurosurg 102:738-744.
25. Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501.
26. Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21(8):1624-36.
27. Goh KY, Poon WS, Chan DT, Ip CP (2005) Tissue plasminogen activator expression in meningiomas and glioblastomas. Clin Neurol Neurosurg 107:296-300.
28. Guillamo JS, de Boüard S, Valable S, Marteau L, Leuraud P, Marie Y, Poupon MF, Parienti JJ, Raymond E, Peschanski M (2009) Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clin Cancer Res 15:3697-3704.
29. Hajjar KA, Harpel PC, Jaffe EA, Nachman RL (1986) Binding of plasminogen to cultured human endothelial cells. J Biol Chem 261:11656-11662.
30. Hajjar KA, Hamel NM, Harpel PC, Nachman RL (1987) Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest 80:1712-1719.
31. Hajjar KA, Jacovina AT, Chacko J (1994) An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 269:21191-21197.
32. Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS, Shaw JA, Walker RA, Pringle JH, Jones JL (2009) Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 11:R24.
33. Hayes MJ, Moss SE (2009) Annexin 2 has a dual role as regulator and effector of v-Src in cell transformation. J Biol Chem 284:10202-10210.
34. Hayes MJ, Rescher U, Gerke V, Moss SE (2004) Annexin-actin interactions. Traffic 5:571-576.
35. Huang KS, Wallner BP, Mattaliano RJ, Tizard R, Burne C, Frey A, Hession C, McGray P, Sinclair LK, Chow EP, et al. (1986) Two human 35 kd inhibitors of phospholipase A2 are related to substrates of pp60v-src and of the epidermal growth factor receptor/kinase. Cell 46:191-199.
36. Huang Y, Jin Y, Yan CH, Yu Y, Bai J, Chen F, Zhao YZ, Fu SB (2008) Involvement of annexin A2 in p53 induced apoptosis in lung cancer. Mol Cell Biochem 309:117-123.
37. Hubaishy I, Jones PG, Bjorge J, Bellagamba C, Fitzpatrick S, Fujita DJ, Wais-man DM (1995) Modulation of annexin II tetramer by tyrosine phos-phorylation. Biochemistry 34:14527-14534.
38. Iwadate Y, Sakaida T, Hiwasa T, Nagai Y, Ishikura H, Takiguchi M, Yamaura A (2004) Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 64:2496-2501.
39. Jacovina AT, Zhong F, Khazanova E, Lev E, Deora AB, Hajjar KA (2001) Neuritogenesis and the nerve growth factor-induced differentiation of PC-12 cells requires annexin II-mediated plasmin generation. J Biol Chem 276:49350-49358.
40. Jacovina AT, Deora AB, Ling Q, Broekman MJ, Almeida D, Greenberg CB, Marcus AJ, Smith JD, Hajjar KA (2009) Homocysteine inhibits neoan-giogenesis in mice through blockade of annexin A2-dependent fibrinoly-sis. J Clin Invest 119:3384-3394.
41. Jahkola T, Toivonen T, Virtanen I, von Smitten K, Nordling S, von Bogus-lawski K, Haglund C, Nevanlinna H, Blomqvist C (1998) Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer 78:1507-1513.
42. Kang HM, Choi KS, Kassam G, Fitzpatrick SL, Kwon M, Waisman DM (1999) Role of annexin II tetramer in plasminogen activation. Trends Cardiovasc Med 9:92-102.
43. Kesavan K, Ratliff J, Johnson EW, Dahlberg W, Asara JM, Misra P, Frangioni JV, Jacoby DB (2010) Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J Biol Chem 285:4366-4374.
44. Kwon M, MacLeod TJ, Zhang Y, Waisman DM (2005) S100A10, annexin A2, and annexin A2 heterotetramer as candidate plasmnogen receptors. Front Biosci 10:300-325.
45. Lampson LA, Wen P, Roman VA, Morris JH, Sarid JA (1992) Disseminating tumor cells and their interactions with leukocytes visualized in the brain. Cancer Res 52:1018-1025.
46. Lampson LA, Lampson MA, Dunne AD (1993) Exploiting the lacZ reporter gene for quantitative analysis of disseminated tumor growth within the brain: use of the lacZ gene product as a tumor antigen, for evaluation of antigenic modulation, and to facilitate image analysis of tumor growth in situ. Cancer Res 53:176-182.
47. Legler JM, Ries LA, Smith MA, Warren JL, Heineman EF, Kaplan RS, Linet MS (1999) Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 91:1382-1390.
48. Levicar N, Dewey RA, Daley E, Bates TE, Davies D, Kos J, Pilkington GJ, Lah TT (2003) Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis. Cancer Gene Ther 10:141-151.
49. Lijnen HR (2001) Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 86:324-333.
50. Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, Hempstead B, Mark WH, Hajjar KA (2004) Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 113:38-48.
51. Maes W, Van GoolSW (2011) Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother 60:153-160.
52. Mai J, Finley RL Jr, Waisman DM, Sloane BF (2000) Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J Biol Chem 275:12806-12812.
53. Martin BM, Wasiewski WW, Fenton JW 2nd, Detwiler TC (1976) Equilibrium binding of thrombin to platelets. Biochemistry 15:4886-4893.
54. McColl BK, Baldwin ME, Roufail S, Freeman C, Moritz RL, Simpson RJ, Alitalo K, Stacker SA, Achen MG (2003) Plasmin activates the lymphan-giogenic growth factors VEGF-C and VEGF-D. J Exp Med 198:863-868.
55. McMahon B, Kwaan HC (2008) The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 36:184-194.
56. Meijne AM, Ruuls-Van Stalle L, Feltkamp CA, McCarthy JB, Roos E (1997) v-src-induced cell shape changes in rat fibroblasts require new gene transcription and precede loss of focal adhesions. Exp Cell Res 234:477-485.
57. Meneses PI, Abrey LE, Hajjar KA, Gultekin SH, Duvoisin RM, Berns KI, Rosenfeld MR (1999) Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth. Clin Cancer Res 5:3689-3694.
58. Mignatti P, Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195.
59. Nolin WB, Emmetsberger J, Bukhari N, Zhang Y, Levine JM, Tsirka SE (2008) tPA-mediated generation of plasmin is catalyzed by the pro- teoglycan NG2. Glia 56:177-189.
60. Nygaard SJ, Haugland HK, Kristoffersen EK, Lund-Johansen M,Laerum OD, Tysnes OB (1998) Expression of annexin II in glioma cell lines and in brain tumor biopsies. J Neurooncol 38:11-18.
61. Ohno Y, Izumi M, Kawamura T, Nishimura T, Mukai K, Tachibana M (2009) Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br J Cancer 101:287-294.
62. Pederson PH, Edvardsen K, Garcia-Cabrera I, Mahesparan R, Thorsen J, Mathison B, Rosenblum ML, Bjerkvig R (1995) Migratory patterns of lac-Z transfected human glioma cells in rat brain. Int J Cancer 62:767-771.
63. Pepper MS (1997) Manipulating angiogenesis. From basic science to the bedside. Arterioscler Thromb Vasc Biol 17:605-619.
64. Pepper MS (2001) Role of the matrix metalloproteinase and plasminogen activator-plasmin systemsinangiogenesis. Arterioscler Thromb Vasc Biol 21:1104-1117.
65. Pistolesi S, Boldrini L, Gisfredi S, De Ieso K, Camacci T, Caniglia M, Lupi G, Leocata P, Basolo F, Pingitore R, Parenti G, Fontanini G (2004) Angio-genesis in intracranial meningiomas: immunohistochemical and molecular study. Neuropathol Appl Neurobiol 30:118-125.
66. Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3:489-501.
67. Reeves SA, Chavez-Kappel C, Davis R, Rosenblum M, Israel MA (1992) Developmental regulation of annexin II (Lipocortin 2) in human brain and expression in high grade glioma. Cancer Res 52:6871-6876.
68. Rella C, Coviello M, Quaranta M, Paradiso A (1993) Tissue-type plasmino-gen activator as marker of functional steroid receptors in human breast cancer. Thromb Res 69:209-220.
69. Repesh LA (1989) A new in vitro assay for quantitating tumor cell invasion. Invasion Metastasis 9:192-208.
70. Roseman BJ, Bollen A, Hsu J, Lamborn K, Israel MA (1994) Annexin II marks astrocytic brain tumors of high histologic grade. Oncol Res 6:561-567.
71. Rosenthal EL, Johnson TM, Allen ED, Apel IJ, Punturieri A, Weiss SJ (1998) Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res 58:5221-5230.
72. Roshy S, Sloane BF, Moin K (2003) Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev 22:271-286.
73. Salvesen GS (2002) Caspases and apoptosis. Essays Biochem 38:9-19.
74. San-Galli F, Vrignaud P, Robert J, Coindre JM, Cohadon F(1989) Assessment of the experimental model oftransplanted C6 glioblastomain Wistar rats. J Neurooncol 7:299- 304.
75. Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC (2006) Angiogenesis-associated protein annexin II in breast cancer: selective ex-pressionin invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 81:146-156.
76. Sharma M, Ownbey RT, Sharma MC (2010) Breast cancer cell surface an-nexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol 88:278-286.
77. + ion channel blockers. J Neurosci 19:5942-5954.
78. Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA (1999) Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 340:77-84.
79. Stephens RW, Brünner N, Janicke F, Schmitt M (1998) The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 52:99-111.
80. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisen-hauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996.
81. Tatenhorst L, Rescher U, Gerke V, Paulus W (2006) Knockdown of annexin 2 decreases migration of human glioma cells in vitro. Neuropathol Appl Neurobiol 32:271-277.
82. Tsatas D, Kaye AH (2003) The role of the plasminogen activation cascade in glioma cell invasion: a review. J Clin Neurosci 10:139-145.
83. Upton AL, Moss SE (1994) Molecular cloning of a novel N-terminal variant of annexin II from rat basophilic leukaemia cells. Biochem J 302:425-428.
84. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized byabnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17:98-110.
85. Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, Master A, Sliwa M, Franciszkiewicz K, Chouaib S, Kaminska B (2008) Microglia-derived TGF-beta as an important regulator of glioblastoma invasion: an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene 27:918-930.
86. Winkler F, Kienast Y, Fuhrmann M, Von Baumgarten L, Burgold S, Mittereg-ger G, Kretzschmar H, Herms J (2009) Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis. Glia 57:1306-1315.
87. Zamecnik J (2005) The extracellular space and matrix of gliomas. Acta Neu-ropathol 110:435-442.
88. Zhai H, Heppner FL, Tsirka SE (2011) Microglia/macrophages promote gli-oma progression. Glia 59:472-485.
89. Zhang F, Zhang L, Zhang B, Wei X, Yang Y, Qi RZ, Ying G, Zhang N, Niu R (2009) Anxa2 plays a critical role in enhanced invasiveness of the multi-drug resistant human breast cancer cells. J Proteome Res 8:5041-5047.
90. Zobiack N, Gerke V, Rescher U (2001) Complex formation and submem-branous localization of annexin 2 and S100A10 in live HepG2 cells. FEBS Lett 500:137-140.